Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action

Oncology Research

Volumn 14, Issue 9, 2004, Pages 447-454

  Dunne, Amanda L ^a   Mothersill, Carmel ^b   Robson, Tracy ^a   Wilson, George D ^c   Hirst, David G ^a,d  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^c Gray Cancer Institute   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Apoptosis; Colon cancer; Docetaxel; G2 M block; Radiosensitization

Indexed keywords

DOCETAXEL; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CYCLE; CELL SURVIVAL; COLON CANCER; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG MECHANISM; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; SENSITIVITY ANALYSIS;

EID: 4644236960     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/0965040041791455     Document Type: Article

References (28)

1. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am. Chem. Soc. 93:2325-2327; 1971.
2. Sinclair, W. K.; Morton, R. A. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat. Res. 29:450-474; 1966.
3. Ingram, M. L.; Redpath, J. L. Subadditive interaction of radiation and taxol in vitro. Int. J. Radiat. Oncol. Biol. Phys. 37:139-144; 1997.
4. Choy, H.; Rodriguez. F.; Koester, M.; Hilsenbeck, S.; Von Hoff, D. D. Investigation of taxol as a potential radiation sensitiser. Cancer 11:3774-3778; 1993.
5. Tishler, R. B.; Schiff, P. B.; Geard, C. R.; Hall, E. J. Taxol: A novel radiation sensitiser. Int. J. Radiat. Oncol. Biol. Phys. 22:613-617; 1992.
6. Sedlak, J.; Sulikova, M.; Chorvath, M.; Hunakova, L.; Novotny, L.; Laginova, V.; Sevcikova, L.; Boljesikova, E.; Chorvath, B. Taxol-enhanced cytotoxic effect of radiation in human promyelocytic leukemia cells: Relative resistance of multidrug-resistant HL-60 cells in vitro. Neoplasma 44:172-177; 1997.
7. Hennequin, C.; Giocanti, N.; Favaudon, V. Interaction of ionizing radiation with paclitaxel (taxol) and docetaxel (taxotere) in HeLa and SQ20B cells. Cancer Res. 56: 1842-1850;1996.
8. Liebmann, J.; Cook, J. A.; Fisher, J.; Teague, D.; Mitchell, J. B. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst. 86:441-446; 1994.
9. Stromberg, J. S.; Lee, Y. J.; Armour, E. P.; Martinez, A. A.; Corry, P. M. Lack of radiosensitisation after paclitaxel treatment of three human carcinoma cell lines. Cancer 75:2262-2268; 1995.
10. Choy, H.; Rodriguez, F.; Wilcox, B.; Koester, S. K.; Degen, D. Radiation sensitising effects of taxotere (RP56976). Proc. Am. Soc. Clin. Oncol. 12:56; 1992.
11. Creane, M.; Seymour, C.; Mothersill, C. Radiobiological effects of docetaxel: A potential radiosensitiser. Int. J. Radiat. Biol. 75:731-737; 1999.
12. Milas, L. Docetaxel/radiation combinations: Rationale and preclinical findings. Clin. Lung Cancer 3(Suppl. 2):S29-36; 2002.
13. Suzuki, M.; Nakamatsu, K.; Kanamori, S.; Masunaga, S.; Nishimura, Y. Additive effects of radiation and docetaxel on murine SCCVII tumors in vivo: Special reference to changes in the cell cycle. Radiat. Res. 159:799-804; 2003.
14. Nabell, L.; Spencer, S. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin. Oncol. 30 (Suppl.)18:89 93; 2003.
15. Choy, H.; De Vore, R. F.; Hande, K. R.; Porter, L. L.; Rosenblatt, P. A.; Slovis, B.; Laporte, K.; Shyr, Y.; Johnson, D. H. A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Clin. Lung Cancer 1(Suppl. 1):S27-31; 2000.
16. Viret, F.; Ychou, M.; Goncalves, A.; Moutardier, V.; Magnin, V.; Braud, A. C.; Dubois, J. B.; Bories, E.; Gravis, G.; Camerlo, J.; Genre, D.; Maraninchi, D.; Viens, P.; Giovannini, M. Docetaxel and radiotherapy and pancreatic cancer. Pancreas 27:214-219; 2003.
17. Karasawa, K.; Katsui, K.; Seki, K.; Kohno, M.; Hanyu, N.; Nasu, S.; Muramatsu, H.; Maebayashi, K.; Mitsuhashi, N.; Haga, S.; Kimura, T.; Takahashi, I. Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer 10:268-274; 2003.
18. Leibovitz, A.; Stinson, J. C.; McCombs, W. B.; McCoy, C. E.; Mazur, K. C.; Mabry, N. D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36: 4562-4569;1976.
19. Fogh, J.; Orfeo, T.; Tiso, J.; Sharkey, F. E. Establishment of human colon carcinoma lines in nude mice. Exp. Cell Biol. 47:136-144; 1979.
20. Gerweck, L. E.; Dullea, R.; Zaidi, S. T.; Budach, W.; Hartford, A. Influence of experimental factors on intrinsic radiosensitivity assays at low doses of radiation: Cell multiplicity. Radiat. Res. 13:361-366; 1994.
21. Milas, L.; Hunter, N. R.; Mason, K. A.; Kurdoglu, B.; Peters, L. J. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 54:3506-3510; 1994.
22. Su, L. N.; Little, J. B. Prolonged cell cycle delay in radioresistant human cell lines transfected with activated ras oncogene and/or simian virus 40 T-antigen. Radiat. Res. 133:73-79; 1993.
23. Biade, S.; Stobbe, C. C.; Chapman, J. D. The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Radiat. Res. 147:416-421; 1997.
24. Pulkkinen, J. O.; Elomaa, L.; Joensuu, H.; Martikainen, P.; Servomma, K.; Grenman, R. Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J. Cancer Res. Clin. Oncol. 122:214-218; 1996.
25. Pulkkinen, J. O.; Pekkola-Heino, K.; Grenman, R. Paclitaxel and irradiation induce apoptosis in squamous cell carcinoma cell lines in an additive way. Anticancer Res. 16:2923-2930; 1996.
26. Haldar, S.; Basu, A.; Croce, C. M. Bcl2 is the guardian of microtubule integrity. Cancer Res. 57:229-233; 1997.
27. Haldar, S.; Chintapalli, J.; Croce, C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1253-1255; 1996.
28. Kraus, L. A.; Samuel, S. K.; Schmid, S. M.; Dykes, D. J.; Waud, W. R.; Bissery, M. C. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest. New Drugs 21:259-268; 2003.